AquaBounty confident that biotech salmon will win FDA approval

02/19/2013 | FoodNavigator

AquaBounty Technologies was disappointed by the FDA's decision to extend the public comment period for its biotech salmon, but it believes the delay won't affect its chances for approval. In 2010, an FDA advisory panel found the salmon posed no risk to safety or the environment. "There has been neither new information nor a clear legal or regulatory issue raised by the FDA since that time," AquaBounty CEO Ronald Stotish said.

View Full Article in:

FoodNavigator

Published in Briefs:

SmartBrief Job Listings for Health Care

Job Title Company Location
President/Chief Executive Officer
MedCost
Winston-Salem, NC
Biotechnology/Pharmaceutical Patent Attorney
Coats and Bennett PLLC
Cary, NC
Director, Payer Marketing
Avalere Health
Washington, DC
Sr. Regulatory Specialist, Biotech Center of Expertise
BASF, The Chemical Co.
San Diego, CA
Chief Medical Officer, Texas Children's Health Plan
Cejka Executive Search for Texas Childre's Health Plan
Houston, TX